IP Library Granted Patent US 11,491,220
Granted Patent B2
US 11,491,220 · App. 16/822,403 · Granted Nov 8, 2022

Methods of producing bioconjugates of

Inventors: Jeroen Geurtsen (Vleuten, NL); Pieter Jan Burghout (Pijnacker, NL); Eveline Marleen Weerdenburg (Uithoorn, NL); Jan Theunis Poolman (Haarlem, NL); Kellen Cristhina Fae (Oegstgeest, NL); Patricia Ibarra Yon (Solothurn, CH); Darren Robert Abbanat (Cornwal, NY); Stefan Jochen Kemmler (Zurich, CH); Michael Thomas Kowarik (Zurich, CH); Manuela Mally (Watt, CH); Veronica Gambillara Fonck (Meilen, CH); Martin Edward Braun (Cham, CH); Maria Paula Carranza Sandmeier (Rudolfstetten, CH)
Assignee: Janssen Pharmaceuticals, Inc.
A61K39/385A61K39/0258A61K39/085A61K39/092A61K39/095A61K39/102A61K39/104A61K39/107A61K47/646A61K2039/6037A61K2039/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,491,220
App. No.
16/822,403
Granted
Nov 8, 2022
Kind
B2
Abstract

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli . (ExPEC).

Claims (16)

1. A method of preparing a bioconjugate of an E. coli O x antigen polysaccharide covalently linked to a carrier protein, the method comprising:

(i) providing a recombinant host cell comprising:

a. a nucleotide sequence of an rfb gene cluster for the O x -antigen polysaccharide;

b. a nucleotide sequence encoding the carrier protein comprising at least one glycosylation site comprising a glycosylation consensus sequence having SEQ ID NO: 1; and

c. a nucleotide sequence encoding an oligosaccharyl transferase PglB y ; and

(ii) culturing the recombinant host cell under conditions for production of the bioconjugate,

wherein:

the O x -antigen is O1A antigen polysaccharide, the PglB y comprises the amino acid mutations of N311V, K482R, D483H, and A669V;

wherein the amino acid mutations are relative to the wild-type PglB having the amino acid sequence of SEQ ID NO: 6, and

wherein the O1A antigen polysaccharide has the structure of:

and n is an integer of 1 to 100.

2. The method of claim 1 , further comprising isolating the bioconjugate from the recombinant host cell.

3. The method of claim 1 , wherein the recombinant host cell is an E. coli cell.

4. The method of claim 1 , wherein the carrier protein is detoxified Exotoxin A of P. aeruginosa (EPA) comprising SEQ ID NO: 3.

5. The method of claim 1 , wherein the carrier protein is selected from the group consisting of detoxified Exotoxin A of P. aeruginosa (EPA), E. coli flagellin (FliC), CRM197, maltose binding protein (MBP), Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of S. aureus , clumping factor A, clumping factor B, E. coli heat labile enterotoxin, detoxified E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified cholera toxin, E. coli Sat protein, the passenger domain of E. coli Sat protein, Streptococcus pneumoniae Pneumolysin, Keyhole limpet hemocyanin (KLH), P. aeruginosa PcrV, outer membrane protein of Neisseria meningitidis (OMPC), and protein D from non-typeable Haemophilus influenzae.

6. The method of claim 1 , wherein the PglB y consists of the amino acid mutations of N311V, K482R, D483H, and A669V.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: IBARRA YON, PATRICIA
To: JANSSEN VACCINES, BRANCH OF CILAG GMBH INTERNATIONAL
Reel/Frame 053659/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: ABBANAT, DARREN ROBERT
To: JANSSEN RESEARCH & DEVELOPMENT, LLC
Reel/Frame 053659/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: GEURTSEN, JEROEN; POOLMAN, JAN THEUNIS; FAE, KELLEN CRISTHINA; BURGHOUT, PIETER JAN; WEERDENBURG, EVELINE M.
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 053659/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: JANSSEN VACCINES, BRANCH OF CILAG GMBH INTERNATIONAL
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 053660/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: JANSSEN RESEARCH & DEVELOPMENT, LLC
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 053660/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: JANSSEN VACCINES & PREVENTION B.V.
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 053660/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2020
From: KEMMLER, STEFAN JOCHEN; KOWARIK, MICHAEL THOMAS; MALLY, MANNELA; GAMBILLARA FONCK, VERONICA; BRAUN, MARTIN EDWARD; CARRANZA SANDMEIER, MARIA PAULA
To: GLAXOSMITHKLINE BIOLOGICALS S.A.
Reel/Frame 052826/0415 →
Continuity (2)
Provisional Application 62819762 · Mar 18, 2019
Related Publication 20200353073A1 · Nov 12, 2020